Jun 17, 2020
PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19
Jun 12, 2020
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 12, 2020
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy
Jun 10, 2020
PTC Therapeutics Launches New "Talent Pipeline Program" to Help Students who Graduated During the 2020 COVID-19 Pandemic
Jun 01, 2020
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
May 28, 2020
PTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform
May 27, 2020
PTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders
May 26, 2020
PTC Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 15, 2020
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2020
PTC Therapeutics to Acquire Censa Pharmaceuticals
May 05, 2020
PTC Therapeutics to Participate at Upcoming Investor Conferences
Apr 30, 2020
PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Apr 28, 2020
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy
Apr 07, 2020
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
Feb 25, 2020
PTC Therapeutics to Participate at Upcoming Investor Conferences
Feb 17, 2020
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
Feb 06, 2020
SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy
Feb 03, 2020
PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference
Feb 03, 2020
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
Jan 13, 2020
PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference